Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma-Reference-Cited by-同舟云学术

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

Published:2016-07-13 Issue:12 Volume:38 Page:1752-1758
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head Neck

Author:

Andtbacka Robert H. I.¹,Agarwala Sanjiv S.²,Ollila David W.³,Hallmeyer Sigrun⁴,Milhem Mohammed⁵,Amatruda Thomas⁶,Nemunaitis John J.⁷,Harrington Kevin J.⁸,Chen Lisa⁹,Shilkrut Mark⁹,Ross Merrick¹⁰,Kaufman Howard L.¹¹

Affiliation:

1. University of Utah Huntsman Cancer InstituteSalt Lake City Utah

2. St. Luke's University Hospital and Temple UniversityPhiladelphia Pennsylvania

3. University of North CarolinaChapel Hill North Carolina

4. Advocate Lutheran General HospitalPark Ridge Illinois

5. University of Iowa Hospitals and ClinicsIowa City Iowa

6. Minnesota OncologyFridley Minnesota

7. Mary Crowley Cancer Research CenterDallas Texas

8. The Institute of Cancer Research/The Royal Marsden HospitalLondon UK

9. Amgen, IncThousand Oaks California

10. The University of Texas MD Anderson Cancer CenterHouston Texas

11. Rutgers Cancer Institute of New JerseyRutgers New Jersey